Trevi Therapeutics, INC. (TRVI) — 8-K Filings

8-K Filings (15)

• Trevi Therapeutics Files 8-K with Material Agreements — Apr 17, 2026 Risk: medium
  Trevi Therapeutics, Inc. filed an 8-K on April 17, 2026, reporting on a material definitive agreement, results of operations, and other events. The filing inclu
• 8-K Filing — Dec 5, 2025
• Trevi Therapeutics Reports Officer and Director Changes — Aug 20, 2025 Risk: medium
  Trevi Therapeutics, Inc. filed an 8-K on August 20, 2025, reporting events as of August 14, 2025. The filing indicates changes related to the departure of direc
• Trevi Therapeutics Files 8-K on Officer/Director Changes — Jun 17, 2025 Risk: medium
  Trevi Therapeutics, Inc. filed an 8-K on June 17, 2025, reporting events that occurred on June 11, 2025. The filing indicates changes related to the departure o
• Trevi Therapeutics Files 8-K: Material Agreement, Other Events — Jun 4, 2025 Risk: medium
  On June 3, 2025, Trevi Therapeutics, Inc. filed an 8-K report detailing a material definitive agreement. The filing also included other events and financial sta
• Trevi Therapeutics Files 8-K for Other Events — Jun 2, 2025 Risk: medium
  Trevi Therapeutics, Inc. filed an 8-K on June 2, 2025, reporting "Other Events." The filing does not contain specific details about the nature of these events,
• Trevi Therapeutics Files 8-K Report — Mar 10, 2025 Risk: low
  On March 10, 2025, Trevi Therapeutics, Inc. filed an 8-K report. The filing indicates "Other Events" as the primary item of disclosure. No specific financial tr
• Trevi Therapeutics Files 8-K on Operations and Financials — Jan 8, 2025 Risk: medium
  On January 8, 2025, Trevi Therapeutics, Inc. filed an 8-K report detailing significant corporate events. The filing indicates the company is providing updates o
• Trevi Therapeutics Files 8-K: Material Agreement & Other Events — Dec 16, 2024 Risk: medium
  On December 15, 2024, Trevi Therapeutics, Inc. entered into a Material Definitive Agreement. The filing also includes other events and financial statements/exhi
• Trevi Therapeutics Files 8-K Report — Dec 12, 2024 Risk: low
  On December 12, 2024, Trevi Therapeutics, Inc. filed an 8-K report. The filing indicates that the company is providing information under "Other Events." No spec
• Trevi Therapeutics Files 8-K Report — Dec 3, 2024 Risk: low
  On December 3, 2024, Trevi Therapeutics, Inc. filed an 8-K report. The filing indicates that the company is providing information under "Other Events" and is no
• Trevi Therapeutics Files 8-K Report — Oct 21, 2024 Risk: low
  On October 21, 2024, Trevi Therapeutics, Inc. filed an 8-K report. The filing indicates "Other Events" as the primary item of disclosure. No specific financial
• Trevi Therapeutics Files 8-K — Oct 4, 2024 Risk: low
  Trevi Therapeutics, Inc. filed an 8-K on October 4, 2024, reporting an event that occurred on October 3, 2024. The filing is categorized under 'Other Events' an
• Trevi Therapeutics Files 8-K on Director and Officer Changes — Oct 1, 2024 Risk: low
  On September 27, 2024, Trevi Therapeutics, Inc. filed an 8-K report detailing changes in its board of directors and executive compensation arrangements. The fil
• Trevi Therapeutics Files 8-K: Shareholder Vote & Financials — Jun 13, 2024 Risk: medium
  On June 13, 2024, Trevi Therapeutics, Inc. filed an 8-K report. The filing indicates that the company is submitting matters to a vote of its security holders an

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX